FDA approves Keytruda plus Lenvima for advanced kidney cancer
Combination treatment reduced the risk of disease progression or death by 61% versus Sutent
Read More
Tag: Lenvima
Keytruda/Lenvima combo shows promise in hard-to-treat cancers
Data shows a range of responses in different tumours
Read More
US rejects MSD/Eisai’s Keytruda Lenvima combo
Regulators rejected accelerated approval as Roche’s combination for the same patient population made it over the line first
Read More
Aimovig leads latest SMC decisions
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read More
NICE recommends Lenvima for advanced liver cancer
The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima, a potentially life-extending treatment for adults with advanced liver cancer.
Read More
Lenvima backed for NHS use to treat liver cancer
NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and Wales as an option for a type of untreated, advanced liver cancer.
Read More
Eisai/MSD’s Lenvima approved in Europe for liver cancer
Eisai and MSD’s Lenvima has won approval in the EU as a first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read More
Lenvima wins green light in liver cancer
Eisai and MSD’s Lenvima (lenvatinib) has been approved in the US for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read More
US ‘breakthrough’ badge for MSD/Eisai cancer combo
A combination therapy being developed by MSD and Eisai for kidney cancer has been awarded Breakthrough Designation in the US.
Read More
NICE bars NHS access to Lenvima, Nexavar for thyroid cancer
NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
Read More
US, EU filings for Eisai’s lenvatinib in liver cancer
Eisai has filed its anticancer drug lenvatinib for liver cancer on both sides of the Atlantic as it seeks to expand the drug’s list of approved uses.
Read More
Eisai’s Lenvima hits liver cancer targets in PhIII trial
A late-stage trial assessing Eisai’s cancer drug Lenvima for hepatocellular carcinoma (HCC) has achieved its primary endpoint, pushing the drug closer to being filed for approval in this setting.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
